Aranesp “Complete Response” Letter Seeks Additional Clinical Data On Monthly Dosing
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen hopes to respond to FDA request with already collected data.
You may also be interested in...
Amgen’s Aranesp Gets Broader Label
FDA provides small boost for safety-challenged ESA.
Amgen’s Aranesp Gets Broader Label
FDA provides small boost for safety-challenged ESA.
Amgen Will Have Day In Court With Roche
The company also reports that sales of its TNF inhibitor Enbrel are “not meeting expectations.”